Company intelligence / Profile preview
Espervita Therapeutics
Ann Arbor, Michigan, USAespervita.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
Espervita Therapeutics' small molecule ACLY inhibitor, EVT0185, demonstrated dramatic tumor reduction and increased immune-mediated destruction of liver tumors in preclinical mouse models, with published results in Nature July 2025[6][8].
- Therapeutic areas
- OncologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Canadian Institutes of Health Research Foundation Grant (academic collaboration/funding)McMaster University (academic research collaboration)
Beyond the preview
Go deeper on Espervita Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Espervita Therapeutics.